Baseline disease activity by sex.
| MTX Monotherapy, N = 284 | ETN Monotherapy, N = 284 | MTX+ETN Combination Therapy, N = 283 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | P, Male vs Femalea,b | Male | Female | P, Male vs Femalea,b | Male | Female | P, Male vs Femalea,b | |
| PsA duration, yrs | 3.8 (0.7) | 3.6 (0.6) | – | 3.8 (0.6) | 2.3 (0.5) | – | 3.1 (0.5) | 2.8 (0.6) | – |
| SJC66 | 14.1 (1.1) | 12.0 (0.6) | – | 11.7 (0.8) | 11.3 (0.8) | – | 9.8 (0.6) | 12.7 (0.9) | 0.008 |
| TJC68 | 20.4 (1.5) | 21.3 (1.1) | – | 18.4 (1.2) | 19.4 (1.3) | – | 17.4 (1.1) | 22.7 (1.4) | 0.004 |
| PGA, 0–100 | 57.0 (1.8) | 59.8 (1.5) | – | 57.5 (1.6) | 59.3 (1.4) | – | 56.1 (1.4) | 59.9 (1.6) | – |
| CRP, mg/L | 10.9 (1.5) | 10.2 (1.2) | – | 11.3 (1.4) | 10.1 (1.1) | – | 7.8 (0.8) | 9.6 (1.2) | – |
| SPARCC enthesitis | 3.2 (0.4) | 4.4 (0.4) | 0.03 | 3.4 (0.3) | 4.0 (0.4) | – | 3.5 (0.3) | 4.8 (0.4) | 0.02 |
| sPGA | 2.6 (0.1) | 2.6 (0.1) | – | 2.7 (0.1) | 2.5 (0.1) | – | 2.6 (0.1) | 2.4 (0.1) | – |
| sPGA status, n (%) | |||||||||
| < 2 | 22 (7.7) | 26 (9.2) | – | 16 (5.6) | 24 (8.5) | – | 22 (7.8) | 30 (10.6) | – |
| ≥ 2 | 101 (35.6) | 132 (46.5) | – | 135 (47.5) | 109 (38.4) | – | 122 (43.1) | 109 (38.5) | – |
| BSA, % | 14.4 (1.8) | 11.3 (1.4) | 0.04 | 12.0 (1.3) | 9.4 (1.2) | – | 11.6 (1.4) | 9.8 (1.2) | – |
| BSA | |||||||||
| < 3%, n (%) | 40 (14.1) | 52 (18.3) | – | 51 (18.0) | 54 (19.0) | – | 51 (18.0) | 55 (19.4) | – |
| ≥ 3%, n (%) | 84 (29.6) | 108 (38.0) | – | 100 (35.2) | 79 (27.8) | – | 93 (32.9) | 84 (29.7) | – |
| HAQ-DI | 1.1 (0.1) | 1.4 (0.1) | < 0.0001 | 1.0 (0.1) | 1.3 (0.1) | 0.0001 | 1.0 (0.1) | 1.3 (0.1) | < 0.0001 |
| PtGA, 0–100 | 57.3 (2.0) | 63.3 (1.8) | 0.02 | 61.9 (1.9) | 64.1 (1.8) | – | 57.9 (1.7) | 64.1 (1.8) | 0.01 |
| PtGAJP, 0–100 | 53.6 (1.8) | 58.0 (1.8) | – | 53.9 (1.9) | 59.4 (1.8) | 0.04 | 51.9 (1.7) | 59.5 (1.9) | 0.003 |
| SF-36 PCS | 36.9 (0.8) | 34.6 (0.6) | 0.02 | 38.4 (0.7) | 37.2 (0.7) | – | 39.5 (0.8) | 35.2 (0.8) | 0.0001 |
| SF-36 MCS | 47.1 (1.1) | 43.7 (1.00) | 0.02 | 46.2 (1.0) | 43.9 (1.1) | – | 47.7 (0.9) | 44.8 (1.0) | 0.03 |
Values are expressed as mean (SE) unless otherwise stated.
↵aP values are nominal.
↵bOnly P values ≤ 0.05 are shown. BSA: body surface area; CRP: C-reactive protein; ETN: etanercept; HAQ-DI: Health Assessment Questionnaire-Disability Index; MTX: methotrexate; MCS: Mental Component Summary; PCS: Physical Component Summary ; PGA: physician global assessment; PsA: psoriatic arthritis; PtGA: patient global assessment of disease activity; PtGAJP: patient global assessment of joint pain; SE: standard error; SF-36: 36-item Short Form Health Survey; SJC66: swollen joint count in 66 joints; SPARCC: Spondyloarthritis Research Consortium of Canada; sPGA: static physician global assessment (of psoriasis); TJC68: tender joint count in 68 joints.